Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Open Access
- 1 January 2013
- journal article
- review article
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 12 (1) , 7
Abstract
Lung cancer is a heterogeneous group of diseases. There has been much research in lung cancer over the past decade which has advanced our ability to treat these patients with a more personalized approach. The scope of this paper is to review the literature and give a broad understanding of the current molecular targets for which we currently have therapies as well as other targets for which we may soon have therapies. Additionally, we will cover some of the issues of resistance with these targeted therapies. The molecular targets we intend to discuss are epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), anaplastic large-cell lymphoma kinase (ALK), KRAS, C-MET/RON, PIK3CA. ROS-1, RET Fibroblast growth factor receptor (FGFR). Ephrins and their receptors, BRAF, and immunotherapies/vaccines. This manuscript only summarizes the work which has been done to date and in no way is meant to be comprehensive.Keywords
This publication has 133 references indexed in Scilit:
- Eph receptors and ephrins in cancer: bidirectional signalling and beyondNature Reviews Cancer, 2010
- The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerDrug Resistance Updates, 2009
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibitionBritish Journal of Cancer, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancersBritish Journal of Cancer, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosisBritish Journal of Cancer, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996